Company announcementCompany-reported
What was reported
MIAMI, Fla., August 24, 2026 – Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”).U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 24, 2026 · Open the source ↗
What the evidence supports
Longeveron furnished a press release to the SEC (Form 8-K, Item 7.01) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineLongeveron Announces 1-for-10 Reverse Stock SplitU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 24, 2026 · Open the source ↗
Press release lead paragraphMIAMI, Fla., August 24, 2026 – Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”).U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 24, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Longeveron Announces 1-for-10 Reverse Stock Split
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.